🔥Hot Off the Press | #CAFs actively drive resistance to ALK inhibitors in #NSCLCs
💡#Alectinib + #Capmatinib and/or #Cilengitide showed better outcome than single agent in suppressing tumor growth in vivo
🌟We provide alectinib, capmatinib and cilengitide for research use